Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Maguire

Showing results (571-580 of 594) with videos related to

Pageof 60
Sort By:
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 3, 2009
Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administrationFrancesca Simonelli, Albert M Maguire, Francesco Testa, et al.
Ophthalmology|June 17, 2022
Adeno-Associated Virus Serotype 2-hCHM Subretinal Delivery to the Macula in Choroideremia: Two-Year Interim Results of an Ongoing Phase I/II Gene Therapy TrialTomas S Aleman, Rachel M Huckfeldt, Leona W Serrano, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 29, 2006
Safety of recombinant adeno-associated virus type 2-RPE65 vector delivered by ocular subretinal injectionSamuel G Jacobson, Gregory M Acland, Gustavo D Aguirre, et al.
Frontiers in Medical Technology|January 20, 2022
Adaptive Manufacturing for Healthcare During the COVID-19 Emergency and BeyondAntoine Vallatos, James M Maguire, Nikolas Pilavakis, et al.
Lancet (London, England)|July 5, 2016
Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trialJean Bennett, Jennifer Wellman, Kathleen A Marshall, et al.
Hepatology (Baltimore, Md.)|July 30, 2025
Erratum: HAF prevents hepatocyte apoptosis and progression to MASH and HCC through transcriptional regulation of the NF-κB pathwayKaren Acuña-Pilarte, Ethan C Reichert, Yangsook Song Green, et al.
Hepatology (Baltimore, Md.)|September 10, 2024
HAF prevents hepatocyte apoptosis and progression to MASH and HCC through transcriptional regulation of the NF-κB pathwayKaren Acuña-Pilarte, Ethan C Reichert, Yangsook Song Green, et al.
European Stroke Journal|April 23, 2019
GISCOME - Genetics of Ischaemic Stroke Functional Outcome network: A protocol for an international multicentre genetic association studyJane M Maguire, Steve Bevan, Tara M Stanne, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 2, 2025
Recovery of cone-mediated vision in Lebercilin associated retinal ciliopathy after gene therapy: One-year results of a phase I/II trialTomas S Aleman, Katherine E Uyhazi, Alejandro J Roman, et al.
Frontiers in Neurology|November 23, 2020
Plasmin Generation Potential and Recanalization in Acute Ischaemic Stroke; an Observational Cohort Study of Stroke Biobank SamplesThomas Lillicrap, Charithani B Keragala, Dominik F Draxler, et al.
Pageof 60

Showing results (571-580 of 594) with videos related to

Sort By:
Pageof 60
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 3, 2009
Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administrationFrancesca Simonelli, Albert M Maguire, Francesco Testa, et al.
Ophthalmology|June 17, 2022
Adeno-Associated Virus Serotype 2-hCHM Subretinal Delivery to the Macula in Choroideremia: Two-Year Interim Results of an Ongoing Phase I/II Gene Therapy TrialTomas S Aleman, Rachel M Huckfeldt, Leona W Serrano, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 29, 2006
Safety of recombinant adeno-associated virus type 2-RPE65 vector delivered by ocular subretinal injectionSamuel G Jacobson, Gregory M Acland, Gustavo D Aguirre, et al.
Frontiers in Medical Technology|January 20, 2022
Adaptive Manufacturing for Healthcare During the COVID-19 Emergency and BeyondAntoine Vallatos, James M Maguire, Nikolas Pilavakis, et al.
Lancet (London, England)|July 5, 2016
Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trialJean Bennett, Jennifer Wellman, Kathleen A Marshall, et al.
Hepatology (Baltimore, Md.)|July 30, 2025
Erratum: HAF prevents hepatocyte apoptosis and progression to MASH and HCC through transcriptional regulation of the NF-κB pathwayKaren Acuña-Pilarte, Ethan C Reichert, Yangsook Song Green, et al.
Hepatology (Baltimore, Md.)|September 10, 2024
HAF prevents hepatocyte apoptosis and progression to MASH and HCC through transcriptional regulation of the NF-κB pathwayKaren Acuña-Pilarte, Ethan C Reichert, Yangsook Song Green, et al.
European Stroke Journal|April 23, 2019
GISCOME - Genetics of Ischaemic Stroke Functional Outcome network: A protocol for an international multicentre genetic association studyJane M Maguire, Steve Bevan, Tara M Stanne, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 2, 2025
Recovery of cone-mediated vision in Lebercilin associated retinal ciliopathy after gene therapy: One-year results of a phase I/II trialTomas S Aleman, Katherine E Uyhazi, Alejandro J Roman, et al.
Frontiers in Neurology|November 23, 2020
Plasmin Generation Potential and Recanalization in Acute Ischaemic Stroke; an Observational Cohort Study of Stroke Biobank SamplesThomas Lillicrap, Charithani B Keragala, Dominik F Draxler, et al.
Pageof 60